Overview – Business Model
Alizé Pharma is a group of independent biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.
Our team is composed of drug development experts and our management and board of directors offer wide international experience. Our strategy is to acquire early stage projects, typically at the discovery or preclinical stage, advance them into clinical development and establish partnerships with pharmaceutical companies to secure both near and long-term revenue streams. Since our creation in 2007, we have raised EUR 20 million from private and institutional investors. We have advanced two programs to the clinical phase and have also operated a first industrial exit with the sale of Alizé Pharma II SAS to Jazz Pharmaceuticals (Nasdaq: JAZZ).
Business Model and Corporate Organization
We operate under an asset-based business model and have pioneered this business model since 2007. This means that each program is developed within a dedicated company which is independently funded, thus providing investors with return on a project-by project basis.
- Alizé Pharma SAS is working on AZP-531, a stabilized peptide analog of unacylated ghrelin, a physiological gastrointestinal peptide. This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and has potential in other behavioral, metabolic and ischemia-related indications.
- Prior to its acquisition by Jazz Pharmaceuticals (Nasdaq: JAZZ) in March 2016, Alizé Pharma II SAS was focused on the development of pegcrisantaspase (ASPAREC®), a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblatic leukemia.
- Alizé Pharma III SAS is dedicated to the I-HBD1 program, a new peptide derived from a physiological protein named IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). I-HBD1 is a new bone anabolic agent to be developed in osteoporosis and some rare metabolic diseases associated with impaired bone formation. This I-HBD1 program is at the lead optimization stage.
The group has raised EUR 20 million from private and institutional investors since its creation. Participating investors in the financing rounds completed so far include the following: